In the second half of the year, pharmaceutical companies are continuing to open a wave of cooperation!

On September 7, Zealand Pharma announced that it has signed a global licensing and development agreement with Novo Nordisk to jointly promote the commercialization
of Zegalogue injection (dasiglucagon).

Data show that Zegalogue is a first-in-class soluble glucagon analogue
.

The drug was approved by the FDA in March 2021 for the treatment of severe hypoglycemia in children 6 years of age and older and adults with diabetes
.

In the second half of the year, pharmaceutical companies are continuing to open a wave of cooperation! Under the terms of the agreement, Zealand will receive an advance payment of DKK 25 million and be eligible for payment for the recent development, regulatory and production milestones of DKK 45 million, as well as a subsequent sales milestone of DKK 220 million
.

Zealand is primarily responsible for regulating, developing and manufacturing activities to support the commercialization of
the drug outside the United States.

In fact, in order to enhance the expansion of R&D pipelines and accelerate the commercialization of products, strong collaboration between pharmaceutical companies has become very common
in the industry.

Since 2022, a large number of domestic and foreign pharmaceutical companies have launched cooperation
in many fields.

For example, on August 30, Sinopharm and Novartis China held a strategic upgrade cooperation seminar and a signing and launching ceremony of the "within reach" project at the Sinopharm Holdings Building in Shanghai, liu Yong, president of Sinopharm Holdings, and Zhang Ying, president of Novartis Innovative Drugs China, attended the signing and launching ceremony, and the relevant project teams of Sinopharm Global Procurement and Supply Chain Service Center, the management and business team of Novartis China's special pharmaceutical retail business attended the signing and launching ceremony
.

In recent years, Sinopharm Holdings and Novartis have actually had in-depth cooperation in a number of projects across the country, such as "Kunpeng Project", "Qilin Project", and professional pharmacy cooperation
.

The strategic cooperation upgrade with State Control is an active exploration
of Novartis' support for all localities to establish standardized diagnosis and treatment inside and outside the hospital and to care for patients.

Especially in the field of psoriasis and chronic urticaria, I hope to work more closely with Sinopharm Holdings in the future to provide more professional and convenient services
for more Chinese patients.

In this regard, Sinopharm Also said that it will fully rely on the distribution network throughout the country, actively exert its strong supply chain service and marketing management capabilities, and constantly innovate service models to help Novartis products to better promote nationwide and provide more high-quality drugs and services to Chinese patients
.

It is worth noting that at present, domestic pharmaceutical companies are still accelerating the "hugging group" and laying out innovative drugs, big health, AI and other fields
.

For example, on August 9, Deqi Pharmaceutical announced that it has reached a long-term strategic cooperation with AI drug research and development company Deruizhi Pharmaceutical to jointly promote the research and development
of the first innovative drug for small molecule anti-tumor.

On May 6, CR Pharmaceutical, CR Sanjiu and Holley Pharma, a wholly-owned subsidiary of Holley Group, signed a strategic cooperation agreement and share transfer agreement
.

According to the content of the agreement, the three parties will carry out comprehensive strategic cooperation in traditional Chinese medicine, the big health industry and other related industries to jointly expand the global market.
.
.
Industry analysis believes that according to the current situation of the industry, cooperation between enterprises is becoming more and more frequent, and the content of cooperation is becoming more and more abundant
.

In the future, under the multi-dimensional cooperation, Chinese and foreign pharmaceutical companies are expected to work together to "go out" and "bring in" to further accelerate; At the same time, the development of domestic pharmaceutical companies will also be more diversified
.

Disclaimer: In no event shall the information or opinions expressed herein constitute investment advice
to any person.